Free Trial

IQVIA (IQV) Stock Forecast & Price Target

$226.78
+1.42 (+0.63%)
(As of 10/8/2024 ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
13

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$266.67
17.59% Upside
According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $266.67. The highest price target for IQV is $300.00, while the lowest price target for IQV is $220.00. The average price target represents a forecasted upside of 17.59% from the current price of $226.78.
Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

Sign Up

IQV Analyst Ratings Over Time

TypeCurrent Forecast
10/9/23 to 10/8/24
1 Month Ago
9/9/23 to 9/8/24
3 Months Ago
7/11/23 to 7/10/24
1 Year Ago
10/9/22 to 10/9/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$266.67$266.67$255.73$251.64
Forecasted Upside17.59% Upside9.71% Upside20.65% Upside26.11% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.78
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside17.66% Upside10,819.51% Upside7.88% Upside
News Sentiment Rating
Positive News

See Recent IQV News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/8/2024Evercore ISI
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$270.00 ➝ $265.00+17.33%
9/20/2024Robert W. Baird
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$251.00 ➝ $256.00+4.65%
9/4/2024Royal Bank of Canada
4 of 5 stars
S. Dodge
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$275.00+10.57%
8/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $288.00+23.01%
7/31/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$266.00 ➝ $242.00+1.34%
7/23/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$270.00 ➝ $280.00+16.57%
7/23/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$295.00 ➝ $300.00+24.28%
7/23/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$292.00 ➝ $300.00+25.18%
7/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$255.00 ➝ $275.00+12.14%
6/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$270.00+23.30%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$290.00+17.29%
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
2/13/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$285.00+30.81%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$190.00 ➝ $225.00+4.52%
10/10/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$250.00 ➝ $229.00+14.76%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$260.00+17.71%
8/2/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $281.00+28.44%
5/1/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$235.00 ➝ $220.00+16.88%
2/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$265.00+14.17%
12/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$251.00+18.44%
10/18/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$290.00 ➝ $270.00+49.02%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:15 PM ET.


Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 3, 2024. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • IQVIA Holdings Inc. reported strong quarterly earnings results, beating the consensus estimate and demonstrating solid financial performance.
  • Recent analyst ratings on IQVIA have been positive, with multiple analysts giving the stock a "buy" or "strong buy" rating, indicating confidence in its future growth potential.
  • Truist Financial raised their price target on IQVIA from $292.00 to $300.00, suggesting further upside potential in the stock.
  • Insider activity shows confidence in the company, with insider Eric Sherbet selling shares at a price above the current market value, indicating belief in future growth.
  • IQVIA Holdings Inc. has a diverse portfolio of services in the medical research industry, positioning it well for long-term growth and stability.

IQVIA
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • Despite positive analyst ratings, there is always inherent risk in investing in any stock, including IQVIA Holdings Inc., due to market volatility and unforeseen events.
  • The stock price of IQVIA Holdings Inc. has experienced fluctuations, which may lead to short-term uncertainty for investors.
  • While the company has shown strong financial performance, there could be regulatory or industry challenges ahead that may impact its growth trajectory.
  • Competition in the medical research industry is intense, and IQVIA Holdings Inc. may face challenges in maintaining its market position against other players.
  • Investors should carefully consider their risk tolerance and investment goals before making decisions related to IQVIA Holdings Inc. stock.

IQV Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $266.67, with a high forecast of $300.00 and a low forecast of $220.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 4 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 17.59% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.82 while the average consensus rating score for "medical" companies is 2.78. Learn more on how IQV compares to other companies.


This page (NYSE:IQV) was last updated on 10/8/2024 by MarketBeat.com Staff
From Our Partners